Distribution of HPV genotypes and the relationship with CIN

Objective: To study the distribution of human papillomavirus (HPV) genotypes in population of hospital opportunistic screening and the relationship with cervical intraepithelial neoplasia (CIN) among women. Materials and Methods: A retrospective analysis was performed in 14,991 women who were undergoing HPV genotype testing and 253 inpatients who were undergoing conization pathological with CIN and with pre-HPV test at Jiangsu University Hospital between July 2013 and July 2015. Results: Of these, 25.99% were infected by HPV and 20.37% for high-risk HPV (hr-HPV), the highest prevalence of hr-HPV and multiple hr-HPV were all in the 55- to 64-year-old group (χ2 = 37.125, p < 0.01, χ2 = 43.668, p < 0.01). The most prevalent genotype is HPV52, then descending order were HPV16 and 58. On the basis of 253 inpatients, CIN I were 78, CIN II were 67, CIN III were 108. Before conization, hr-HPV positive in CIN I lesions were 74.36% (58/78) and CIN II were 94.03% (63/67), while in CIN III lesions there were 94.44% (102/108) (χ2 =17.936, p < 0.01). The most frequent HPV genotype was HPV 16, followed by HPV 58 and 52. Infection with multiple- hr-HPV seemed to have no relationship with the severity of pathology increased (χ2 =1.888, p > 0.01). Conclusion: This study established the prevalence of HPV genotypes that is similar to the population of CIN, except HPV 16 and HPV 52, 58 were also found in a large proportion of women, HPV 18 was not the most important. Therefore, in the future, a HPV vaccine covering HPV 52/16/58 should be used in this region compared to the currently available vaccine for the prevention strategy in the population.

Human papillomavirus (HPV); Genotype; Cervical intraepithelial neoplasia (CIN).

[1] Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., et al.: “Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012”. Int. J. Cancer, 2015, 136, E359.

[2] Li S., Hu T., Lv W., Zhou H., Li X., Yang R., et al.: “Changes in prevalence and clinical characteristics of cervical cancer in the People’s Republic of China: a study of 10,012 cases from a nationwide working group”. Oncologist, 2013, 18, 1101.

[3] Giorgi R.P., Franceschi S., Ronco G.: “HPV prevalence and accuracy of HPV testing to detect high grade cervical intraepithelial neoplasia”. Int. J. Cancer, 2012, 130, 1387.

[4] Nam K., Chung S., Kim J., Jeon S., Bae D.: “Factors associated with HPV persistence after conization in patients with negative margins”. J. Gynecol. Oncol., 2009, 20, 91.

[5] McCredie M.R., Sharples K.J., Paul C., Baranyai J., Medley G., Jones R.W., et al.: “Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study”. Lancet Oncol., 2008, 9, 425.

[6] Ho G.Y., Burk R.D., Klein S., Kadish A.S., Chang C.J., Palan P., et al.: “Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia”. J. Natl. Cancer Inst., 1995, 87, 1365.

[7] Wang R., Guo X.L., Wisman G.B., Schuuring E., Wang W.F., Zeng Z.Y.: “Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China”. BMC Infect Dis., 2015, 15, 257.

[8] Argyri E., Papaspyridakos S., Tsimplaki E., Michala L., Myriokefalitaki E., Papassideri I., et al.: “A cross sectional study of HPV type prevalence according to age and cytology”. BMC Infect. Dis., 2013, 13, 53.

[9] Yuce K., Pinar A., Salman M.C., Alp A., Sayal B., Dogan S., Hascelik G.: “Detection and genotyping of cervical HPV with simultaneous cervical cytology in Turkish women: a hospital-based study”. Arch. Gynecol. Obstet., 2012, 286, 203.

[10] Agarossi A., Ferrazzi E., Parazzini F., Perno C.F., Ghisoni L.: “Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy”. J. Med. Virol., 2009, 81, 529.

[11] Anderson L., O'Rorke M., Jamison J., Wilson R., Gavin A., HPV Working Group members: “Prevalence of human papillomavirus in women attending cervical screening in the UK and Ireland: new data from northern Ireland and a systematic review and meta-analysis”. J. Med. Virol., 2013, 85, 295.

[12] de Sanjosé S., Diaz M., Castellsagué X., Clifford G., Bruni L., Muñoz N., Bosch F.X.: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis”. Lancet Infect. Dis., 2007, 7, 453.

[13] Vaccarella S., Franceschi S., Herrero R., Muñoz N., Snijders P.J., Clifford G.M., et al.: “IARC HPV Prevalence Surveys Study Group. Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys”. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 326.

[14] Pista A.; de Oliveira C.F., Cunha M.J., Paixao M.T., Real O.: “Prevalence of human papillomavirus infection in women in Portugal: The CLEOPATRE Portugal Study”. Int. J. Gynecol. Cancer, 2011, 21, 1150.

[15] Balbi G., Napolitano A., Giordano F., Capuano S., Manganaro M.A., Di Martino L., et al.: “Role of the association of high-risk HPV identified by real-time PCR in cervical preneoplastic lesions”. Eur. J. Gynaecol. Oncol., 2012, 33, 467.

[16] Trottier H., Mahmud S., Costa M.C., Sobrinho J.P., Duarte Franco E., Rohan T.E., et al.: “Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 1274.

[17] Cuschieri K.S., Cubie H.A., Whitley M.W., Gilkison G., Arends M.J., Graham C., McGoogan E.: “Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study”. J. Clin. Pathol., 2005, 58, 946.

[18] Ye J., Cheng X., Chen X., Ye F., Lü W., Xie X.: “Prevalence and risk profile of cervical Human papillomavirus infection in Zhejiang Province, southeast China: a population-based study”. Virol. J., 2010, 7, 66.

[19] De Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al.: “Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional survey”. Lancet Oncol., 2010, 11, 1048.

[20] Choi Y.J., Park J.S.: “Clinical significance of human papillomavirus genotyping”. J. Gynecol. Oncol., 2016, 27, e21.

[21] Schiller J.T., Castellsagué X., Villa L.L., Hildesheim A.: “An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results”. Vaccine, 2008, 26, K53.

[22] Markowitz L.E., Dunne E.F., Saraiya M., Chesson H.W., Curtis C.R., Gee J., et al.: “Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)”. MMWR Recomm. Rep., 2014, 63, 1.

[23] Joura E.A, Giuliano A.R., Iversen O.E., Bouchard C., Mao C., Mehlsen J., et al.: “A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women”. N. Engl. J. Med., 2015, 372, 711.